NTRA

SEC source: 0001646382-26-000021 · form4-09162026_090901.xml · nonDerivative · entry 5

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,207,142

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.58 to $332.52 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000021 · form4-09162026_090901.xml · nonDerivative · entry 4

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,208,142

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.55 to $331.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000021 · form4-09162026_090901.xml · nonDerivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,211,636

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.54 to $330.52 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000021 · form4-09162026_090901.xml · nonDerivative · entry 2

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,217,842

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.53 to $329.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000021 · form4-09162026_090901.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,223,857

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.50 to $328.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 6

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,225,394

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.50 to $329.74 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 5

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,226,694

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.50 to $329.45 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 4

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,242,458

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.50 to $328.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 3

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,260,391

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $326.50 to $327.49 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 2

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,270,947

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.50 to $326.4950 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646382-26-000019 · form4-09112026_090901.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,274,594

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2026.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.49 to $325.34 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,859

F5 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023.

SEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,019

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,619

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000028 · form4-09032026_090901.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,019

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000022 · form4-09032026_090901.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,199

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

SEC source: 0001646649-26-000030 · form4-08142026_090801.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230,464

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.23 to $325.46 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010135-26-000020 · form4-08282026_090801.xml · nonDerivative · entry 2

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,257

F2 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 12, 2022.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 10

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,464

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 9

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,953

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 8

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 237,053

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.62 to $318.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 7

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 237,253

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.10 to $316.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 6

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,364

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.04 to $315.67 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 5

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,964

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.9500 to $314.7150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 4

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,814

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $312.5950 to $313.3150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 3

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,714

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $311.5050 to $312.5000 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 2

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,114

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $309.9250 to $310.5250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001646649-26-000029 · form4-08072026_090801.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,514

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.

SEC source: 0001646382-26-000018 · form4-08072026_090805.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Indirect · By spouse

Disclosed balance after: 2,000

F1 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

SEC source: 0002010135-26-000020 · form4-08282026_090801.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,774

F1 · shares: On August 12, 2022, the Reporting Person was granted performance-based Restricted Stock Units (RSUs) covering 50,000 shares of Common Stock vesting in tranches upon the Issuer achieving certain specified financial and operating metrics. On August 6, 2026, the achievement of milestones for the vesting of RSUs covering 20,000 shares of Common Stock was certified.

SEC source: 0001697362-26-000017 · form4-08052026_090812.xml · nonDerivative · entry 2

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,637

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as modified on September 10, 2025.

SEC source: 0002010135-26-000019 · form4-08052026_090808.xml · nonDerivative · entry 1

Fesko John · CIK 0002010135 · PRESIDENT, CHIEF BUS. OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,774

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 7

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,019

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.63 to $268.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 6

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,147

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.1550 to $268.1150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 5

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,380

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.27 to $265.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 4

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,572

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6550 to $264.2400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 3

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,519

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.1500 to $261.8250 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 2

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,719

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.

SEC source: 0002010019-26-000024 · form4-08052026_090806.xml · nonDerivative · entry 1

Moshkevich Solomon · CIK 0002010019 · PRESIDENT, CLINICALDIAGNOSTICS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,019

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 7

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,897

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.8350 to $268.7700 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 6

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,509

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.58 to $267.54 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 5

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,805

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 4

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 100,885

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.29 to $264.24 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 3

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,561

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 2

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,631

F2 · shares: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023, as amended on December 2, 2024, and as further amended on March 5, 2026.

SEC source: 0001711968-26-000021 · form4-08052026_090810.xml · nonDerivative · entry 1

Chapman Steven Leonard · CIK 0001711968 · Director · CEO AND PRESIDENT

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,791

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001697362-26-000017 · form4-08052026_090812.xml · nonDerivative · entry 1

Brophy Michael Burkes · CIK 0001697362 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,115

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001646382-26-000017 · form4-08052026_090803.xml · nonDerivative · entry 1

Rabinowitz Matthew · CIK 0001646382 · Director · EXECUTIVE CHAIRMAN

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,275,394

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001857843-26-000024 · form4-08052026_090805.xml · nonDerivative · entry 1

RABINOWITZ DANIEL · CIK 0001857843 · SEC. AND CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,073

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.

SEC source: 0001646649-26-000028 · form4-08052026_090801.xml · nonDerivative · entry 1

Sheena Jonathan · CIK 0001646649 · Director · CO-FOUNDER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 245,614

F1 · shares: The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.